Abilify and Terminal insomnia - a phase IV clinical study of FDA data

Summary:

Terminal insomnia is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are male, 20-29 old, have been taking the drug for < 1 month also take Topamax, and have Schizophrenia.

The phase IV clinical study analyzes which people have Terminal insomnia when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,454 Abilify users. Check the latest studies of Abilify.

What is Terminal insomnia?

Terminal insomnia (a sleep disorder in which there is an inability to fall asleep or to stay asleep as long as desired) is found to be associated with 203 drugs and 345 conditions by eHealthMe. Check the latest studies of Terminal insomnia.

On Jul, 11, 2026

97,308 people reported to have side effects when taking Abilify.
Among them, 18 people (0.02%) have Terminal insomnia.

Among these 18 people:

How long have people been on Abilify when they have Terminal insomnia? *

What is the gender of people who have Terminal insomnia when taking Abilify? *

female: 47.06 %
male: 52.94 %

What is the age of people who have Terminal insomnia when taking Abilify? *

What are other drugs people take besides Abilify? *

What are other side effects people have besides Terminal insomnia? *

Abnormal Behavior: 3 people, 16.67%
Suicide Attempt: 3 people, 16.67%
Soliloquy: 3 people, 16.67%
Stress And Anxiety: 3 people, 16.67%
Logorrhea: 3 people, 16.67%
Spinal Compression Fracture (fracture due to spinal compression on bone): 3 people, 16.67%
Initial Insomnia (feeling of inadequate or poor-quality sleep): 2 people, 11.11%
Tremor (trembling or shaking movements in one or more parts of your body): 2 people, 11.11%
Activities Of Daily Living Impaired: 2 people, 11.11%
Fatigue (feeling of tiredness): 2 people, 11.11%

What are the existing conditions these people have? *

Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 5 people, 27.78%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 11.11%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 11.11%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 2 people, 11.11%
Stress And Anxiety: 1 person, 5.56%
Sleep Disorder: 1 person, 5.56%
Postpartum Depression (depression suffered by a mother following childbirth): 1 person, 5.56%
Ovarian Cancer (cancer of ovary): 1 person, 5.56%
Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 1 person, 5.56%
Hiv Infection: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Terminal insomnia?

- Check whether Terminal insomnia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,454 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Terminal insomnia:

Terminal insomnia (203 drugs)

Browse all the conditions that are associated with Terminal insomnia:

Terminal insomnia (345 conditions)

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.